Advertisement
U.S. Markets open in 2 hrs 59 mins
S&P Futures
5,967.50 +9.25 (+0.16%) Dow Futures
43,976.00 +75.00 (+0.17%) Nasdaq Futures
20,933.75 +39.75 (+0.19%) Russell 2000 Futures
2,416.60 +10.80 (+0.45%) Crude Oil
70.89 -0.80 (-1.12%) Gold
2,670.90 -5.40 (-0.20%)
BriaCell Therapeutics Corp. (BCTX)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Follow
At close: 04:00PM EST
After hours:
| Previous Close | 0.7255 |
| Open | 0.7300 |
| Bid | 0.6747 x 100 |
| Ask | 0.7303 x 100 |
| Day's Range | 0.6700 - 0.7400 |
| 52 Week Range | 0.4600 - 5.9700 |
| Volume | |
| Avg. Volume | 4,986,182 |
| Market Cap | 25.509M |
| Beta (5Y Monthly) | 1.83 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2900 |
| Earnings Date | Dec 12, 2024 - Dec 16, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.00 |
GlobeNewswireBriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium®, December 10 – 13
Five BriaCell poster presentations to highlight updated survival and key biomarker data from Phase 2 trial of Bria-IMT™ plus immune check point inhibitor in metastatic breast cancerPresentations include planned Phase 3 study design expanding use of Bria-IMT™ + CPI to any cancer patient with central nervous system (CNS) metastases PHILADELPHIA and VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company
- MT Newswires
BriaCell Higher as it Reports "Standard-Beating" Survival Data From Phase 2 Study
BriaCell Higher as it Reports "Standard-Beating" Survival Data From Phase 2 Study
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.